For Healthcare Professionals

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

clipboard-pencil

About the study

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis.
  2. Participants must have received at least 24 months but not more than 60 months of any adjuvant ET, from time of adjuvant ET initiation.
  3. Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor.
  4. Must have an increased risk of disease recurrence based on clinical-pathological risk features.
  5. Have a Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group scale.
  6. Have adequate organ function.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Have any evidence of metastatic disease (including contralateral ALN) or inflammatory breast cancer at primary breast cancer diagnosis.
  2. Participants with more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET.
  3. Participants who have completed or discontinued prior adjuvant ET >6 months prior to screening.
  4. Participants with a history of previous breast cancer are excluded, with the exception of ipsilateral DCIS treated by locoregional therapy alone ≥5 years ago.
  5. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of study intervention.
  6. Participant has previously received ET of any duration for breast cancer prevention (tamoxifen or AIs) or raloxifene.
  7. Participants with a history of any other cancer.
  8. Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-317-615-4559Email iconEmail Study Center

Study Details


Contition

Breast Neoplasms

Age

18+

Phase

PHASE3

Participants Needed

6000

Est. Completion Date

Mar 15, 2032

Treatment Type

INTERVENTIONAL


Sponsor

Eli Lilly and Company

ClinicalTrials.gov NCT Identifier

NCT05514054

Study Number

J2J-MC-JZLH

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.